Does aspirin use reduce cardiovascular risk in diabetes?
The use of aspirin for the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus is controversial. According to the findings of a Japanese trial, aspirin does not reduce the risk of cardiovascular events in this group of patients, unless they are aged 65 years and above.
Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425, USA. colwelja@musc.edu
John A
JA
Colwell
D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000150:complications* / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*
D010975:Platelet Aggregation Inhibitors; D001241:Aspirin